Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Long-Term Trial Investigating Safety and Efficacy of TransCon hGH in Children With Growth Hormone Deficiency Who Have Completed a Prior TransCon hGH Clinical Trial
Sponsor: Ascendis Pharma A/S
Summary
A multicenter, phase 3, long-term extension trial of TransCon hGH administered once-weekly in children with growth hormone deficiency (GHD) who previously participated in a phase 3 TransCon hGH trial. Approximately 300 children (males and females) with GHD will be included. All study participants will receive TransCon hGH. This is a global trial that will be conducted in, but not limited to, the United States, Poland, Bulgaria, Ukraine, Armenia, Russia and Australia.
Official title: enliGHten: A Multicenter, Phase 3, Long-Term, Open-Label Trial Investigating Safety and Efficacy of TransCon hGH Administered Once-Weekly in Children With Growth Hormone Deficiency (GHD) Who Have Completed a Prior TransCon hGH Clinical Trial
Key Details
Gender
All
Age Range
1 Year - 18 Years
Study Type
INTERVENTIONAL
Enrollment
298
Start Date
2017-12-19
Completion Date
2023-02-21
Last Updated
2026-07-07
Healthy Volunteers
No
Conditions
Interventions
TransCon hGH
Once weekly subcutaneous injection of TransCon hGH
Locations (42)
Ascendis Pharma Investigational Site
Birmingham, Alabama, United States
Ascendis Pharma Investigational Site
Los Angeles, California, United States
Ascendis Pharma Investigational Site
Orange, California, United States
Ascendis Pharma Investigational Site
Sacramento, California, United States
Ascendis Pharma Investigational Site
Centennial, Colorado, United States
Ascendis Pharma Investigational Site
Jacksonville, Florida, United States
Ascendis Pharma Investigational Site
Orlando, Florida, United States
Ascendis Pharma Investigational Site
Tallahassee, Florida, United States
Ascendis Pharma Investigational Site
Saint Paul, Minnesota, United States
Ascendis Pharma Investigational Site
Jackson, Mississippi, United States
Ascendis Pharma Investigational Site
Lebanon, New Hampshire, United States
Ascendis Pharma Investigational Site
Mineola, New York, United States
Ascendis Pharma Investigational Site
New York, New York, United States
Ascendis Pharma Investigational Site
Cleveland, Ohio, United States
Ascendis Pharma Investigational Site
Oklahoma City, Oklahoma, United States
Ascendis Pharma Investigational Site
Portland, Oregon, United States
Ascendis Pharma Investigational Site
Portland, Oregon, United States
Ascendis Pharma Investigational Site
Dallas, Texas, United States
Ascendis Pharma Investigational Site
Fort Worth, Texas, United States
Ascendis Pharma Investigational Site
Charlottesville, Virginia, United States
Ascendis Pharma Investigational Site
Norfolk, Virginia, United States
Ascendis Pharma Investigational Site
Tacoma, Washington, United States
Ascendis Pharma Investigational Site
Yerevan, Armenia
Ascendis Pharma Investigational Site
Clayton, Victoria, Australia
Ascendis Pharma Investigational Site
Minsk, Belarus
Ascendis Pharma Investigational Site
Varna, Bulgaria
Ascendis Pharma Investigational Site
Tbilisi, Georgia
Ascendis Pharma Investigational Site
Athens, Greece
Ascendis Pharma Investigational Site
Auckland, New Zealand
Ascendis Pharma Investigational Site
Gdansk, Poland
Ascendis Pharma Investigational Site
Warsaw, Poland
Ascendis Pharma Investigational Site
Izhevsk, Russia
Ascendis Pharma Investigational Site
Krasnoyarsk, Russia
Ascendis Pharma Investigational Site
Moscow, Russia
Ascendis Pharma Investigational Site
Saint Petersburg, Russia
Ascendis Pharma Investigational Site
Saratov, Russia
Ascendis Pharma Investigational Site
Ufa, Russia
Ascendis Pharma Investigational Site
Vologda, Russia
Ascendis Pharma Investigational Site
Voronezh, Russia
Ascendis Pharma Investigational Site
Kharkiv, Ukraine
Ascendis Pharma Investigational Site
Kyiv, Ukraine
Ascendis Pharma Investigational Site
Odesa, Ukraine